Journal issues > Issue 4, August 2018 > Highlights in aggressive lymphoma

Highlights in aggressive lymphoma

SUMMARY

EHA 2018 featured several eagerly awaited presentations on Hodgkin lymphoma. This included subgroup data of the ECHELON-1 trial in patients with high-risk features and data of a PET-based treatment de-escalation study. In non-Hodgkin lymphoma, the RELEVANCE study assessed the chemotherapy-free lenalidomide-rituximab combination as 1^st line treatment for follicular lymphoma. In diffuse-large-B-cell lymphoma, updates were presented of the key studies evaluating CAR T-cell therapy and polatuzumab vedotin was found to improve the survival in relapsed/refractory patients.

(BELG J HEMATOL 2018;9(4):152–6)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top